IOV-2001
- Generic Name
- IOV-2001
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
Not Applicable
Not yet recruiting
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoid LeukemiaB-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Beijing GoBroad Hospital
- Target Recruit Count
- 213
- Registration Number
- NCT06389305
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
Phase 1
Completed
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04155710
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Baptist Cancer Center, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath